CPIs disrupt intrinsic and tumor-induced suppressor mechanisms restricting a spontaneous anti-tumor immune response, as evidenced by associations between tumor PD-L1 expression, tumor-infiltrating lymphocytes (TILs), tumor mutational burden (TMB), neoantigen load, and response to therapy (6–9). The gene discussed is CD274; the disease is neoplasm.